In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.
|Articles|March 15, 2022
Daily Medication Pearl: Losartan Potassium (Cozaar)
Author(s)Saro Arakelians, PharmD
Cozaar is indicated for the treatment of hypertension in adults and children over 6 years of age.
Advertisement
Medication Pearl of the Day: Losartan Potassium (Cozaar)
Indication: Cozaar is indicated for the treatment of
Insight:
- Dosing: Usual adult dose 50 mg once daily.
- Dosage forms: Tablets 25 mg, 50 mg, and 100 mg.
- Adverse events: Most common adverse reactions (incidence ≥2% and greater than placebo) are dizziness, upper respiratory infection, nasal congestion, and back pain.
- Mechanism of action: Losartan and its principal active metabolite block the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor found in many tissues
- Manufacturer: Merck
References:
Advertisement
Related to this article
Pharmacy Times featured experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
Sea buckthorn is a commonly used herbal for respiratory health—US pharmacists are knowledgeable in educating patients on herbals, especially during cold and influenza season.
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
Hiddo J. L. Heerspink, PharmD, PhD, discusses SOLSTICE elecoglipron data, finerenone in FSGS, and glucagon’s kidney effects from ASN Kidney Week 2026.
Pharmacy performance measures should recognize clinical interventions, patient counseling, prescriber collaboration, and outcomes—not prescription volume alone.
CMS’s GLP-1 Bridge demo bypasses Part D to cover select obesity drugs, with a $50 monthly copay, PA workflow, and strict eligibility through 2027.
Two Kidney Week 2026 analyses tie SGLT2 inhibitors to kidney, CV, and survival gains in T2D, yet over half of patients with diabetic CKD receive neither.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Medicare GLP-1 Bridge Runs Outside Part D and Pharmacy Teams Need a Different Workflow
2
Beyond Prescription Volume: Measuring the Pharmacist’s Value
3
FDA Approves Talazoparib With Enzalutamide for HRR-Mutated Metastatic Prostate Cancer
4
GLP-1 RAs, Finerenone, and CKD: Key Data From Kidney Week 2026
5